新冠病毒抗体药物研发进展及展望分析  

Developm ent and Prospect of Antibody Drugs for SARS-CoV-2

作　　者：武瑞君 李治非 张鑫 濮润[1] 敖翼[1] 孙燕荣 WU Rui-jun;LI Zhi-fei;ZHANG Xin;PU Run;AO Yi;SUN Yan-rong(Cliina National Center for Biotechnology Development,Beijing 100039,China)

机构地区：[1]中国生物技术发展中心,北京100039

出　　处：《中国生物工程杂志》2020年第5期1-6,共6页China Biotechnology

摘　　要：抗体药物以其独特的作用机制和靶向性强、特异性好等优点,在恶性肿瘤、自身免疫性疾病、感染类疾病的诊断和治疗中发挥着越来越重要的作用,成为国际创新药物研发的热点。新冠肺炎(COVID-19)疫情发生以来,国内外多家研究机构和企业正在加快推进新冠病毒(SARS-CoV-2)抗体药物的开发。在此情势下,认真分析抗体药物现状和趋势,梳理国内外新冠病毒抗体药物研究进展,明确我国当前抗体药物创新的机遇、挑战和建议,对加快我国药物自主创新研发具有重要意义。With their unique advantages of high affinity and high specificity,antibody drugs have played an increasingly important role in the diagnosis and treatment of malignant tumors,autoimmune diseases,and infectious diseases,becoming the focus of international innovative drug research.Since the outbreak of COVID-19,many research institutions and enterprises at home and abroad are in accelerated development of antibody drugs.In this situation,a systematic analysis of the status and trends of antibody drugs,the research progress of new antibody drugs for SARS-CoV-2,and the opportunities,challenges and suggestions for current antibody drug innovation in China is of great significance to promote the independent innovation of antibody drugs in China.

关 键 词：新冠病毒 抗体药物 药物研发 新冠肺炎 

分 类 号：Q78[生物学—分子生物学]